Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T08:46:27.509Z Has data issue: false hasContentIssue false
  • English
  • Français

Growth Hormone Responses to Apomorphine HCl in Schizophrenic Patients on Drug Holidays and at Relapse

Published online by Cambridge University Press:  29 January 2018

J. M. Cleghorn ,
G. M. Brown ,
P. J. Brown ,
R. D. Kaplan ,
S. W. Dermer ,
D. J. MacCrimmon  and
J. Mitton
J. M. Cleghorn
Affiliation:
Department of Psychiatry, McMaster University, Hamilton, Ontario, Canada
G. M. Brown
Affiliation:
Department of Neurosciences, McMaster University
P. J. Brown
Affiliation:
Department of Psychiatry, McMaster University
R. D. Kaplan
Affiliation:
Department of Psychiatry, McMaster University
S. W. Dermer
Affiliation:
Department of Psychiatry, McMaster University; Community and Social and Vocational Rehabilitation Schizophrenia Inc., 350 King Street East, Hamilton
D. J. MacCrimmon
Affiliation:
Department of Psychiatry, McMaster University; Hamilton Psychiatric Hospital
J. Mitton
Affiliation:
Department of Psychiatry, McMaster University, Hamilton
Get access Rights & Permissions [Opens in a new window]

Summary

In nine schizophrenic patients on drug holiday, growth hormone (GH) response to apomorphine HCl 0.75 mg (APO) was compared with normal control data. Patients were tested at two month intervals for up to 14 months. Seven patients relapsed, and of these, five had exaggerated GH responses to APO at that time. Of these five, three had exaggerated GH responses to APO prior to clinical deterioration. Further work is required to determine whether this test can be a useful predictor of relapse.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 142 , Issue 5 , May 1983 , pp. 482 - 488
Copyright
Copyright © 1983 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brown, G. M., Cleghorn, J. M. & Boyne, T. (in press) Psychoneuroendocrinology in growth hormone: An update. in The Anterior Pituitary (ed. Bhatnagar, A. S.). New York: Raven Press.Google Scholar
Brown, G. M., Verhaegen, H., Van Wimersma, G. & Brugmans, J. (1981) Endocrine effects of domperidone: a peripheral dopamine blocking agent. Clinical Endocrinology, 15, 275–82.Google Scholar
Cleghorn, J. M., Brown, G. M., Brown, P. J., Kaplan, R. D. & Mitton, J. (1983) Growth hormone responses to graded doses of apomorphine HCl in schizophrenia. Submitted to Biological Psychiatry. Google Scholar
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 66–8.Google Scholar
Davis, J. M. (1976) Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry, 33, 858–61.Google Scholar
Feldman, F. & Susselman, S. (1945) A note on apomorphine as a sedative. American Journal of Psychiatry, 102, 403–5.CrossRefGoogle ScholarPubMed
Ferrier, I. N., Cotes, P. M., Crow, T. J. & Johnstone, E. C. (1982) Gonadotrophin secretion abnormalities in chronic schizophrenia. Psychological Medicine, 12, 263–73.Google Scholar
Holuster, L., Davis, K. & Berger, P. (1980) Apomorphine in schizophrenia. Compendium of Psychopharmacology, 4, 277–80.Google Scholar
Huseman, C. A., Kugler, J. A. & Schneider, I. G. (1980) Mechanism of dopaminergic suppression of gonadotrophin secretion in man. Journal of Clinical Endocrinology and Metabolism, 51, 209–13.CrossRefGoogle Scholar
Jeste, D. V. (1981) Apomorphine response in schizophrenia. Scientific Proceedings, American Psychiatric Association. Number 79, page 163.Google Scholar
Krawiecka, M., Goldberg, D. & Vaughan, M. (1977) A standardized assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica, 55, 299–303.CrossRefGoogle ScholarPubMed
Lal, S., Tolis, C., Martin, J. B., Brown, G. M. & Guyda, H. (1975) Effect of clonidine on growth hormone, prolactin luteinizing hormone, follicle-stimulating hormone, and thyroid stimulating hormone in the serum of normal men. Journal of Clinical Endocrinology and Metabolism, 41, 827–32.CrossRefGoogle ScholarPubMed
Meltzer, H. Y., Busch, D. & Fang, V. S. (in press) Neuroendocrine abnormalities in schizophrenia: Prolactin, growth hormone, and gonadotropins. In Neuroendocrinology and Psychiatric Disorder (eds. Brown, G. M., Reichlin, S., and Koslow, S.), New York: Raven Press.Google Scholar
Smith, R., Tamminga, C. & Davis, J. (1977) Effects of apomorphine on schizophrenic symptoms. Journal of Neural Transmission, 40, 171–6.Google Scholar
Spitzer, R. L., Endicott, J. & Robins, E. (1978) Research diagnostic criteria: Rationale and reliability. Archives of General Psychiatry, 35, 773–82.Google Scholar
Weitzman, E. D. (1980) Neuroendocrine rhythms and the sleep cycle. In Handbook of Biological Psychiatry (Part III) (eds. van Praag, H., Lader, M., Rafaelson, O., Sachar, E., Dekker, M.), New York: Basel.Google Scholar
Zuckerman, M. (1979) Sensation Seeking, New York: Lawrence Erlbaum Associates.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.